Bo Lundgren

Stockholm University

Head of Unit, Biochemical and Cellular Assay Facility, DDD Platform

Key publications

Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses.
Luttens A, Gullberg H, Abdurakhmanov E, Vo DD, Akaberi D, Talibov VO, Nekhotiaeva N, Vangeel L, De Jonghe S, Jochmans D, Krambrich J, Tas A, Lundgren B, Gravenfors Y, Craig AJ, Atilaw Y, Sandström A, Moodie LWK, Lundkvist Å, van Hemert MJ, Neyts J, Lennerstrand J, Kihlberg J, Sandberg K, Danielson UH, Carlsson J.
J Am Chem Soc. 2022 Feb 23;144(7):2905-2920. doi: 10.1021/jacs.1c08402. Epub 2022 Feb 10.
PMID: 35142215

Screening persistent organic pollutants for effects on testosterone and estrogen synthesis at human-relevant concentrations using H295R cells in 96-well plates.
Strand D, Nylander E, Höglund A, Lundgren B, Martin JW, Karlsson O.
Cell Biol Toxicol. 2024 Aug 13;40(1):69. doi: 10.1007/s10565-024-09902-4.
PMID: 39136868

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.
Johansson P, Krona C, Kundu S, Doroszko M, Baskaran S, Schmidt L, Vinel C, Almstedt E, Elgendy R, Elfineh L, Gallant C, Lundsten S, Ferrer Gago FJ, Hakkarainen A, Sipilä P, Häggblad M, Martens U, Lundgren B, Frigault MM, Lane DP, Swartling FJ, Uhrbom L, Nestor M, Marino S, Nelander S.
Cell Rep. 2020 Jul 14;32(2):107897. doi: 10.1016/j.celrep.2020.107897.
PMID: 32668248

Research focus

Facility established 2010 at SciLifeLab as a high throughput siRNA genomic and small molecules screening facility (GMT, SU, Director: Thomas Helleday).
Became an active facility in the national Drug Discovery and Development platform 2014 (Director: Per Arvidson, KI). and a part of DBB, SU.
The facility has presently four FTE employed and is equipped with state of the art instrumentation: non-contact transfer liquid handling, instrument for plating biochemical and cellular assays and analyze in micro plates (384 well format) as well as dedicated cell culture capabilities.

Our function is to provide the small molecule and biologics DDD projects with validated biochemical and cellular assays at industrial / pharma quality. The facility provides the platform projects with assay support, data analyze and reporting of data to the DDD database as well as providing the project teams with expertise target cell model and assays, validation of target, In Vitro Toxicology, predictive toxicology using “In Silico tools” and general pre-clinical support

Our aim is to deliver reliable and project relevant data to the DDD projects in order to facilitate the successful development of new drugs and treatments together with Swedish academic researchers.

Group members

Hjalmar Gullberg
Katharina. Klöditz
Melania Minoia
Natalia Nekhotiaeva

Last updated: 2024-11-26

Content Responsible: David Gotthold(david.gotthold@scilifelab.se)